NewAmsterdam Pharma Co N.V.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $22.5M | $45.6M | $14.1M | $102.7M | — |
| Operating income | -$225.7M | -$176.3M | -$183.0M | -$3.6M | -$35.0M |
| Operating expenses | $248.2M | $221.9M | $197.1M | $106.3M | $35.0M |
| Cash from operations | -$147.8M | -$158.6M | -$141.2M | $10.7M | -$29.5M |
| Capital expenditure | $246,000 | $672,000 | $24,000 | $221,000 | $24,000 |
| Free cash flow | -$148.0M | -$159.2M | -$141.2M | $10.4M | -$29.5M |
| Total assets | $769.3M | $864.6M | $347.1M | $478.5M | — |
| Total liabilities | $85.9M | $107.1M | $58.7M | $48.4M | — |
Shares outstanding 116.9M · Free float 68.9%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.